Literature DB >> 18477469

Inhibition of GSK-3 reduces infarct volume and improves neurobehavioral functions.

Seong-Ho Koh1, A Rum Yoo, Dae-Il Chang, Se J Hwang, Seung H Kim.   

Abstract

In the present study, we have investigated the effects of glycogen synthase kinase-3 (GSK-3) inhibition on infarct volume and neurobehavioral functions in a focal cerebral ischemia model. To achieve our goals, GSK-3 inhibitor II or VIII was injected at several time points and in varing dosages. GSK-3 inhibitor VIII was more effective than inhibitor II, and infarct volume and water content in the VIII group were significantly decreased 24h after the onset of ischemic stroke, as compared with the control group. These protective effects were associated with reductions of TUNEL-positive cells, neutrophil infiltration, glucose levels after ischemia, and GSK-3 enzyme activity. In addition, expressions of death and inflammation-related signals decreased and those of survival-related signals increased. Lastly, neurobehavioral functions were restored to a greater extent in the VIII group than in the control group. Together, these results suggest that GSK-3 inhibition reduces infarct volume and restores neurobehavioral functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18477469     DOI: 10.1016/j.bbrc.2008.05.006

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

Review 1.  Targeting protein kinases in central nervous system disorders.

Authors:  Laura K Chico; Linda J Van Eldik; D Martin Watterson
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

2.  A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia-reperfusion injury in mice.

Authors:  Dmitriy N Atochin; Igor A Schepetkin; Andrei I Khlebnikov; Victor I Seledtsov; Helen Swanson; Mark T Quinn; Paul L Huang
Journal:  Neurosci Lett       Date:  2016-02-26       Impact factor: 3.046

3.  Inhibition of glycogen synthase kinase 3 beta ameliorates liver ischemia reperfusion injury by way of an interleukin-10-mediated immune regulatory mechanism.

Authors:  Feng Ren; Zhongping Duan; Qiao Cheng; Xiuda Shen; Feng Gao; Li Bai; Jun Liu; Ronald W Busuttil; Jerzy W Kupiec-Weglinski; Yuan Zhai
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

Review 4.  Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.

Authors:  Zhi-fei Wang; Emily Bame Fessler; De-Maw Chuang
Journal:  Acta Pharmacol Sin       Date:  2011-11-07       Impact factor: 6.150

5.  Cortical neurons develop insulin resistance and blunted Akt signaling: a potential mechanism contributing to enhanced ischemic injury in diabetes.

Authors:  Bhumsoo Kim; Kelli A Sullivan; Carey Backus; Eva L Feldman
Journal:  Antioxid Redox Signal       Date:  2011-03-08       Impact factor: 8.401

6.  Early Activation of Phosphatidylinositol 3-Kinase after Ischemic Stroke Reduces Infarct Volume and Improves Long-Term Behavior.

Authors:  Young Seo Kim; Arum Yoo; Jeong Woo Son; Hyun Young Kim; Young-Jun Lee; Sejin Hwang; Kyu-Yong Lee; Young Joo Lee; Cenk Ayata; Hyung-Hwan Kim; Seong-Ho Koh
Journal:  Mol Neurobiol       Date:  2016-09-02       Impact factor: 5.590

7.  Lipoprotein receptor-related protein-6 protects the brain from ischemic injury.

Authors:  Takato Abe; Ping Zhou; Katherine Jackman; Carmen Capone; Barbara Casolla; Karin Hochrainer; Timo Kahles; Margaret Elizabeth Ross; Josef Anrather; Costantino Iadecola
Journal:  Stroke       Date:  2013-06-06       Impact factor: 7.914

8.  Glia-Like Cells from Late-Passage Human MSCs Protect Against Ischemic Stroke Through IGFBP-4.

Authors:  Jeong-Woo Son; Jihye Park; Ye Eun Kim; Jieun Ha; Dong Woo Park; Mi-Sook Chang; Seong-Ho Koh
Journal:  Mol Neurobiol       Date:  2019-05-12       Impact factor: 5.590

9.  Delayed treatment of 6-Bromoindirubin-3'-oxime stimulates neurogenesis and functional recovery after focal ischemic stroke in mice.

Authors:  Li-Li Wang; Jimei Li; Xiaohuan Gu; Ling Wei; Shan Ping Yu
Journal:  Int J Dev Neurosci       Date:  2017-01-19       Impact factor: 2.457

10.  Activation of AKT1/GSK-3β/β-Catenin-TRIM11/Survivin Pathway by Novel GSK-3β Inhibitor Promotes Neuron Cell Survival: Study in Differentiated SH-SY5Y Cells in OGD Model.

Authors:  B S Darshit; M Ramanathan
Journal:  Mol Neurobiol       Date:  2015-12-11       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.